WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma
Open Access
- 6 February 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (2) , e0115635
Abstract
The wild-type p53-induced phosphatase 1 (WIP1) is a serine/threonine phosphatase that negatively regulates multiple proteins involved in DNA damage response including p53, CHK2, Histone H2AX, and ATM, and it has been shown to be overexpressed or amplified in human cancers including breast and ovarian cancers. We examined WIP1 mRNA levels across multiple tumor types and found the highest levels in breast cancer, leukemia, medulloblastoma and neuroblastoma. Neuroblastoma is an exclusively TP53 wild type tumor at diagnosis and inhibition of p53 is required for tumorigenesis. Neuroblastomas in particular have previously been shown to have 17q amplification, harboring the WIP1 (PPM1D) gene and associated with poor clinical outcome. We therefore sought to determine whether inhibiting WIP1 with a selective antagonist, GSK2830371, can attenuate neuroblastoma cell growth through reactivation of p53 mediated tumor suppression. Neuroblastoma cell lines with wild-type TP53 alleles were highly sensitive to GSK2830371 treatment, while cell lines with mutant TP53 were resistant to GSK2830371. The majority of tested neuroblastoma cell lines with copy number gains of the PPM1D locus were also TP53 wild-type and sensitive to GSK2830371A; in contrast cell lines with no copy gain of PPM1D were mixed in their sensitivity to WIP1 inhibition, with the primary determinant being TP53 mutational status. Since WIP1 is involved in the cellular response to DNA damage and drugs used in neuroblastoma treatment induce apoptosis through DNA damage, we sought to determine whether GSK2830371 could act synergistically with standard of care chemotherapeutics. Treatment of wild-type TP53 neuroblastoma cell lines with both GSK2830371 and either doxorubicin or carboplatin resulted in enhanced cell death, mediated through caspase 3/7 induction, as compared to either agent alone. Our data suggests that WIP1 inhibition represents a novel therapeutic approach to neuroblastoma that could be integrated with current chemotherapeutic approaches.Keywords
This publication has 50 references indexed in Scilit:
- Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpointJournal of Cell Biology, 2013
- Wild-type p53-induced Phosphatase 1 Dephosphorylates Histone Variant γ-H2AX and Suppresses DNA Double Strand Break RepairJournal of Biological Chemistry, 2010
- High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed NeuroblastomaClinical Cancer Research, 2010
- PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell CarcinomasClinical Cancer Research, 2009
- Regenerative capacity of neural precursors in the adult mammalian brain is under the control of p53Neurobiology of Aging, 2009
- The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathwaysCancer and Metastasis Reviews, 2008
- DNA damage signalling guards against activated oncogenes and tumour progressionOncogene, 2007
- Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1DJournal of Neuro-Oncology, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisNature, 2005